Cobalt Technologies Inc. Overview
Cobalt Technologies was a Silicon Valley industrial biotechnology start-up that tried to commercialize n-butanol made from non-food cellulosic biomass. It used non-genetically-modified Clostridium strains and, originally, a biofilm-based continuous fermentation process. It presented bio-butanol both as a renewable chemical and as a platform intermediate for jet fuel, plastics and synthetic rubber. The company raised more than USD 90 million across at least five venture rounds. It built a library of 240 strains covering eight species and claimed production costs below USD 700 per tonne. It never reached commercial-scale production. After a management change around 2012, a move away from its core biofilm technology and a long period of public silence, it could not secure further funding. Its headquarters closed and its equipment, intellectual property and strain library were auctioned in 2015. It is now of historical interest only.
Cobalt specialized in producing biobutanol from cellulosic feedstocks, including corn cobs, forestry residues (treetops and limbs) and beetle-killed pine [V]. No annual report exists, so the company's own filed description cannot be quoted.
Business model. The company was a pre-commercial technology developer. Its intended model, as far as public statements show, combined technology licensing and joint development with industrial partners, rather than building and owning plants alone [R]. No product, service, subscription or licensing revenue mix was ever disclosed.
Value chain position. Cobalt sat upstream, between biomass suppliers and chemical or fuel producers. Its technology covered biomass-to-sugar conversion, fermentation to n-butanol and strain improvement [V].
Customer types and end-markets. Target end-markets were n-butanol for paints, coatings and solvents; renewable jet fuel; and butadiene for synthetic rubber [V]. No commercial customers or offtake volumes were disclosed.
Independent characterization. Cobalt was a venture-funded process-technology company whose value lay in its strains and patents, not in operating assets or revenue.
Strategy
There have been no initiatives in the last 24 months; the company has been defunct since 2015. Historically, its strategy had three phases.
-
From 2005 to about 2012, it pursued low-capital continuous biofilm fermentation of cellulosic sugars to n-butanol [V].
-
From 2010, it extended butanol into higher-value derivatives: jet fuel with the US Navy and butadiene with Asian partners [V].
-
After about 2012, it pivoted toward retrofitting distressed ethanol plants, which made it resemble its competitors and weakened its differentiation [V].
Medium-term financial targets and guidance were never published.
Products & Services
The company had no commercial product catalog. Its technology assets, as listed in the 2015 liquidation summary, were as follows.
The cost figures are the company's own claims from a sale document and were never demonstrated at commercial scale. Pricing models, launch years and named flagship offerings are not publicly disclosed.
Product Portfolio
| Asset | Description | Disclosed metric | Source |
|---|---|---|---|
n-Butanol fermentation process | Clostridium-based fermentation of C5 and C6 sugars; originally continuous fixed-bed biofilm reactors | Claimed production cost below USD 700 per tonne | [V] |
Biomass-to-sugar technology | Proprietary pretreatment and hydrolysis | Claimed sugar cost below USD 220 per tonne | [V] |
Strain library | Product-tolerant, non-GMO organisms | 240 strains, 8 species | [V] |
Strain improvement methods | Patented | Number of patents not disclosed | [V] |
Butanol-to-jet pathway | Licensed from the US Navy | Terms not disclosed | [V] |
Butanol-to-butadiene pathway | Development work with Asian partners | — | [V] |
“—” = not publicly disclosed.
Financial Narrative
No audited financial statements were ever published. Revenue, gross profit, operating income, EBITDA, net income, EPS, dividends, balance sheet items, cash flow items and all ratios are not publicly disclosed for any year. No chartable table is provided, because any number entered would be fabricated.
The only verified financial facts are funding events.
Commentary. The company consumed more than USD 90 million over roughly ten years without reaching commercial revenue. The pattern is typical of first-generation advanced biofuel ventures of the 2005–2015 period.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Funding Fact Details
| Funding fact | Amount (USD Mn) |
|---|---|
Series C, 2008 | 25 |
Series D, 2011 | 20 |
Cumulative capital invested by 2015, through at least Series E | More than 90 |
Analyst Conclusions
There is no guidance, no consensus and no forward catalyst. Bull and bear cases do not apply to a defunct company.
Monitorables. The only open questions are where the strain library and patents went after the auction, and whether any successor is using them.
Analyst verdict. No public company named Cobalt Technologies Inc. could be found. The matching entity is a private Californian biobutanol developer that failed in 2015, and it is not an investable or commercially active counterparty. Its history is still instructive. The company had real technical assets: a large non-GMO strain library, patented strain improvement methods and credible partners in Fluor, the US Navy and Rhodia/Solvay. It raised more than USD 90 million. It failed for three reasons. Scale-up of cellulosic fermentation took longer and cost more than venture investors would fund. The company abandoned the biofilm process that set it apart in favour of ethanol-plant retrofits that competitors could also offer. And the oil price fall from 2014 removed the price advantage that bio-based butanol needed, just as the collapse of other advanced biofuel ventures closed the funding window.
If the target is a different company (for example Cobalt Holdings plc, Cobalt Blue Holdings, Cobalt Blockchain or the private cybersecurity firm Cobalt), a reference URL, ticker or country of listing will allow a full 22-section profile. If the defunct biobutanol company is indeed the target, the items tagged [R] should be checked against the original 2008–2013 press releases, and the "public company" label should be corrected to "private, defunct".
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure |
|---|---|---|
Rick Wilson | Chief Executive Officer | 2008 to c. 2012 |
Bob Mayer | Chief Executive Officer | c. 2012 to 2015 |
Andy Meyer | President | — |
Carole Cobb | Chief Operating Officer | — |
David Walther | Vice President, R&D | — |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor | Approach | Note |
|---|---|---|
Green Biologics | n-Butanol by Clostridium fermentation | Seen in 2015 as making the steadiest progress |
Gevo | Isobutanol | Listed on NASDAQ |
Butamax (BP / DuPont joint venture) | Isobutanol | — |
TetraVitae Bioscience | n-Butanol | Assets acquired by Eastman |
Cathay Industrial Biotech | n-Butanol | Public offering withdrawn |
METabolic EXplorer | Bio-based chemicals | — |
Celtic Renewables | Butanol from whisky residues | — |
Abengoa | Guerbet route from ethanol | — |
Petrochemical n-butanol producers | Propylene-based oxo process | The price-setting incumbents |
Recent Developments
The company has not operated since 2015. The last material events were the closure and auction reported in June 2015 and the creditor claims deadline of 15 October 2015 [V].



